ArticleBMC cancer2026
Diagnostic accuracy of an AI-based pathologic response assessment in locally advanced non-small cell lung cancer after neoadjuvant chemo-immunotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNeoadjuvant chemo-immunotherapy has shown promise in improving survival outcomes for non-small cell lung cancer (NSCLC) patients, with pathologic response serving as a critical predictor of long-term outcomes. However, manual assessment of pathologic response is labor-intensive and subject to inter-observer variability. This study aimed to develop an automated AI-based solution to address these limitations.
methodsWe developed an AI-powered patch-based image analysis model to quantify residual viable tumor (RVT) in hematoxylin and eosin (H&E)-stained whole slide images. The model was evaluated on resected specimens from 47 NSCLC patients treated with neoadjuvant chemo-immunotherapy. The AI-derived estimates of RVT were compared with visual assessments by a board-certified pathologist. Statistical analysis included Pearson’s correlation for continuous tumor estimation and Cohen’s Kappa for concordance in major pathologic response (MPR) and pathologic complete response (pCR) classification.
resultsThe AI model demonstrated a strong correlation with the pathologist’s continuous estimation of RVT (r = 0.77, p < 0.001, confidence interval [CI]: 0.73–0.81). In the assessment of clinical endpoints, the model achieved an 89.36% concordance rate for MPR (Kappa = 0.79, p < 0.001, CI: 0.61–0.96) and 89.36% concordance rate for pCR (Kappa = 0.56, p < 0.001, CI: 0.24–0.89) when compared with the board-certified pathologist.
conclusionsOur AI-powered model demonstrates potential as a decision-support tool for pathologic response assessments in NSCLC patients treated with neoadjuvant chemo-immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.